Ginkgo Bioworks
NEWS
Boston-based Ginkgo Bioworks has been having a banner year and doesn’t show any signs of stopping with its recent string of collaboration announcements.
Ginkgo has signed multiple collaborations, announced a breakthrough in manufacturing mRNA vaccine components, and landed an SPAC deal.
Antheia has joined forces with Ginkgo Bioworks to strengthen its efforts in developing and producing essential medicines to treat a wide range of diseases.
Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is now touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.
Biopharma and life sciences companies strengthen their leadership teams with these Movers & Shakers.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
Less than two weeks after Ginkgo Bioworks announced a merger with SPAC Soaring Eagle Acquisition Corp., it announced a collaboration partnership with Biogen.
Biotechnology firm Ginkgo Bioworks is going public via a merger with Soaring Eagle Acquisition Corp.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.
JOBS
IN THE PRESS